Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
MORRISTOWN, N.J., Nov. 06, 2017 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced the sale of a non-core product, Cedax® (ceftibuten capsules and ceftibuten for oral suspension), a third-generation cephalosporin antibiotic for the treatment of acute bacterial exacerbations of chronic bronchitis and middle ear infection, to SI Pharmaceuticals, LLC, for $2 million in gross cash proceeds.
Cedax® was discontinued by Pernix in 2016 and the Company has not generated any sales from this product in 2017.
“This transaction provides us the opportunity to monetize a non-core product that was previously discontinued without impacting our sales or profitability,” said John Sedor, Chairman and CEO of Pernix Therapeutics. “We are pleased to further strengthen our balance sheet with this transaction.”
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company is currently focused on the therapeutic areas of Neurology and Pain, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its internal sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT
Investor Relations
Bob Yedid
LifeSci Advisors, LLC
[email protected]
